secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001108205-24-000061
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis Q2 net loss $11.8M; emavusertib gets EU ODD for PCNSL
-----------------------------------------------------------

- Net loss of $11.8M ($2.03/sh) vs $12.0M ($2.47) in Q2 2023; revenue $2.5M from Erivedge royalties.
- Cash, equivalents and investments $28.4M; expected to fund operations into Q1 2025.
- EC granted Orphan Drug Designation to emavusertib for treatment of primary CNS lymphoma.
- Initial data for 15-20 R/R PCNSL patients expected late 2024; ASH presentation planned.
- Updated TakeAim Leukemia data and frontline triplet combo safety data due late 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000110820524000061/0001108205-24-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000110820524000061/cris-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001108205-24-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer